Folgen
Yakkala Prasanna Anjaneyulu
Yakkala Prasanna Anjaneyulu
PhD Scholar
Bestätigte E-Mail-Adresse bei osu.edu
Titel
Zitiert von
Zitiert von
Jahr
Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
PA Yakkala, NR Penumallu, S Shafi, A Kamal
Pharmaceuticals 16 (10), 1456, 2023
392023
Regioselective C–H alkylation and alkenylation at the C5 position of 2-amino-1, 4-naphthoquinones with maleimides under Rh (iii) catalysis
PA Yakkala, D Giri, B Chaudhary, P Auti, S Sharma
Organic Chemistry Frontiers 6 (14), 2441-2446, 2019
362019
Rh (III)-catalyzed [3+ 2] annulation via C–H activation: Direct access to trifluoromethyl-substituted indenamines and aminoindanes
B Chaudhary, P Auti, SD Shinde, PA Yakkala, D Giri, S Sharma
Organic letters 21 (8), 2763-2767, 2019
302019
Pyridine-based 1, 2, 4-triazolo-tethered indole conjugates potentially affecting TNKS and PI3K in colorectal cancer
PA Yakkala, SR Panda, VGM Naidu, S Shafi, A Kamal
ACS Medicinal Chemistry Letters 14 (3), 260-269, 2023
152023
Synthesis and Cytotoxic Activity of 1,2,4-Triazolo-Linked Bis-Indolyl Conjugates as Dual Inhibitors of Tankyrase and PI3K
PA Yakkala, SR Panda, S Shafi, VGM Naidu, MS Yar, PN Ubanako, ...
Molecules 27 (21), 7642, 2022
132022
Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design
K Haider, A Sharma, MS Yar, PA Yakkala, S Shafi, A Kamal
Expert Opinion on Drug Discovery 17 (3), 247-257, 2022
82022
Multicomponent Domino Reaction for Concise Access to 2-Amino-Substituted 1, 3, 4 Oxadiazoles via Smiles Rearrangement
PA Yakkala, IA Khan, SR Dannarm, J Aboti, R Sonti, S Shafi, A Kamal
The Journal of Organic Chemistry 88 (17), 12216-12223, 2023
52023
An update on the development on tubulin inhibitors for the treatment of solid tumors
PA Yakkalaa, S Rahaman, PSL Soukya, SA Begum, A Kamal
Expert Opinion on Therapeutic Targets 28 (3), 193-220, 2024
42024
PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer
PA Yakkala, F Naaz, S Shafi, A Kamal
Expert Opinion on Therapeutic Targets 28 (3), 159-177, 2024
32024
5‐Arylidene‐2,4‐thiazolidinediones as Cysteine Protease Inhibitors against Leishmania Donovani
S Sharma, P Anjaneyulu Yakkala, MA Beg, S Tanwar, I Latief, A Khan, ...
ChemistrySelect 8 (29), e202302415, 2023
22023
Design and Synthesis of Michael Acceptor‐Based Peptidyl β‐Nitrostyrenes as 3CLpro Inhibitors of SARS‐CoV‐2
S Sharma, PA Yakkala, J Aboti, I Latief, MA Ansari, WH Khan, S Shafi
ChemistrySelect 8 (24), e202300912, 2023
22023
Development and Evaluation of Bis-benzothiazoles as a New Class of Benzothiazoles Targeting DprE1 as Antitubercular Agents
R Samoon, S Sau, A Roy, KK Parida, K Sharma, PA Yakkala, ...
ACS Infectious Diseases 10 (9), 3320-3331, 2024
12024
Oxindoline Containing Thiazolidine‐4‐one Tethered Triazoles Act as Antimitotic Agents by Targeting Microtubule Dynamics
S Shahjahan, LT Naraharisetti, A Begum, PA Yakkala, ...
ChemistrySelect 9 (17), e202400539, 2024
12024
Dual-targeting inhibitors involving tubulin for the treatment of cancer
PA Yakkala, A Kamal
Bioorganic Chemistry, 108116, 2024
2024
Synthesis and Development of Heterocyclic Hybrids as Potential Anti Cancer Agents
YP Anjaneyulu
Delhi, 0
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–15